I

nvestorsand the media

Company News

Home > Investors & media > Company News

Sinopep-Allsino Biopharmaceutical Co Ltd. attended the TIDES EUROPE 2022

Source: Sinopep Preparations     Time: [2022-11-18]

From November 16th to 18th, 2022, TIDES Europe 2022, a high-profile pharmaceutial event in the field of oligonucleotides and peptides, has been held at the Austria Center in Vienna, Austria. This conference focused on oligonucleotide CMC, oligonucleotide discovery/preclinical/clinical research, peptide CMC, peptide discovery/preclinical/clinical research, mRNA therapeutics and genome editing.

As a biopharmaceutical company focusing on the R&D and production of peptide drugs and small molecule chemical drugs, Sinopep-Allsino has been delighted to participate in this event. Sinopep-Allsino shared its successful experience in complex oligonucleotides and peptide CRDMO cases, and exhibited how Sinopep-Allsino provided customers with GMP production services from preclinical sample preparation to oligonucleotide APIs/FDF that met domestic and foreign regulations.

Sinopep-Allsino is a biopharmaceutical enterprise focusing on peptide drugs and small molecule drugs, oligonucleotide drugs with a strategic layout, and a combination of independent research and development and customized research and production. Its subsidiary Apextide focuses on complex oligonucleotides and peptide CRDMOs, providing preclinical research and One-stop service from production to commercial production.

Apextide is an oligonucleotide and peptide CRDMO platform that are equipped with the most advanced Cytiva equipment in the world. It provides "one-stop" services from laboratory research, process development, clinical phase production, to commercial manufacturing, laboratory scale (gram level), pilot test to commercial production scale (hundred grams to kilograms). Apextide is also equipped with QHPLC/UPLC, LC-MS, LC-MS/MS, IC, GC, GC-MS, ICP-MS and other state-of-art analysis facilities, which provides a quality guarantee for oligonucleotide structure characterization, analytical method development and verification, GMP production control and final product release testing, stability studies, etc.

Mobile version

Contact

Sales Department:
+86-571-88671216 (FDF)
+86-571-88672696 (API and intermediates)